RESEARCH TRIANGLE PARK, N.C., July 1, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
Research Triangle Park, NC — (Marketwired) –June 25, 2024 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARKÒ Permanent J-code 0208 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million […]
RESEARCH TRIANGLE PARK, N.C., May 7, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that […]
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI® in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and […]
March 19, 2024 RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and […]
March 17, 2024 Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory […]
February 29, 2024~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty […]
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK®Which Occurred on September 20, 2022 ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, […]
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ Research Triangle Park, NC, August 22, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]
Read More… from FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR